Predicting checkpoint blocker response
Good news for Siamab with Stn
Making the (pre)clinical rounds
Biomarker for breast cancer
Reducing cancer trial barriers
Immatics and Genmab partner on next-gen cancer immunotherapies
BAY 1905254 is good to go
Solid tumors and ‘switchable’ CAR-T cells
Mogamulizumab makes a mark
Out of the starting gate
The next gen of CAR-T
Detecting cancer through ultra-low detection of microRNA in blood
Double the sequencing
China follows U.S. and Europe in approving Alecensa
Cancer cell evolution and drug discovery
Touring the oncology landscape
AI imaging
Precision medicine and pancreatic cancer
A cancer coalition
Agios, CStone to pursue ivosidenib development
‘ADAPT’ or fail?
Agenus discovery enhances activity of cancer-fighting antibodies
Sonnet completes discovery phase of immuno-oncology program
A new bladder cancer biomarker
Guest Commentary: How genomic testing is redefining cancer research
Looking for novel cancer therapeutics
Making cancer fight itself
Tislelizumab impresses in Phase 2 trial
Immuno-oncology roundup
Proper prediction in prostate cancer
Special Focus on Cancer Research News
Oncology vs. the supervillains
Several companies release recent news related to tackling some of the toughest cancers
Special Focus on Cancer Research News
In the pink with oncology R&D
A roundup of recent research and clinical work within the realm of breast cancer
DDNews
Cancer Research Exclusive
A new kind of PEARL
Recent work with nanoparticles offers a new approach to photo-thermal cancer therapies
PAGE UTILITIES
PRINT CURRENT PAGE
SEND THIS PAGE TO A COLLEAGUE
CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600 | Fax: 440-331-7563
Home
|
About Us
|
Editor's Choice
|
News
|
Opinion
|
Top 5
|
Video
|
Links
© Copyright 2018 Old River Publications LLC. All righs reserved. | Web site managed and designed by
OffWhite.
